AI Engines For more Details: Perplexity Kagi Labs You
Muscle Relaxation: Alcuronium chloride works by competitively binding to nicotinic acetylcholine receptors at the neuromuscular junction, thereby blocking the action of acetylcholine and preventing muscle contraction. This results in muscle relaxation, which is essential for facilitating surgical procedures or maintaining a patient's airway during mechanical ventilation.
Anesthesia: Alcuronium chloride is primarily used as an adjunct to general anesthesia to achieve skeletal muscle relaxation during surgery. By paralyzing skeletal muscles, alcuronium chloride helps prevent involuntary movements, muscle contractions, or reflex responses that could interfere with surgical access or compromise patient safety during anesthesia.
Endotracheal Intubation: Alcuronium chloride may be administered to facilitate endotracheal intubation, particularly in emergency situations or when rapid sequence induction (RSI) anesthesia is required. By inducing muscle relaxation, alcuronium chloride facilitates the insertion of an endotracheal tube into the trachea, allowing for mechanical ventilation and airway management during anesthesia.
Duration of Action: Alcuronium chloride has an intermediate duration of action, with onset of action occurring within minutes of administration and duration of effect lasting approximately 30 to 60 minutes. The duration of action may vary depending on factors such as the dose administered, patient characteristics, and concurrent use of other medications.
Reversal Agents: The effects of alcuronium chloride can be reversed with the administration of acetylcholinesterase inhibitors such as neostigmine or edrophonium. These agents work by increasing the concentration of acetylcholine at the neuromuscular junction, thereby overcoming the blockade caused by alcuronium chloride and restoring neuromuscular function.
Titration and Monitoring: Alcuronium chloride should be administered and titrated carefully based on individual patient factors such as weight, age, and underlying medical conditions. Neuromuscular function should be monitored continuously using neuromuscular monitoring devices to assess the depth of muscle relaxation and guide dosing adjustments as needed.
Cardiovascular Effects: Alcuronium chloride may cause cardiovascular effects such as hypotension or bradycardia, particularly at higher doses or with rapid administration. Patients should be closely monitored for hemodynamic changes during anesthesia, and supportive measures such as fluid resuscitation or vasopressor administration may be necessary to maintain adequate perfusion.
Respiratory Effects: Alcuronium chloride can lead to respiratory muscle paralysis and respiratory depression, particularly if adequate ventilation is not provided during anesthesia. Mechanical ventilation and oxygenation should be initiated as needed to maintain adequate gas exchange and prevent hypoxemia.
Contraindications: Alcuronium chloride is contraindicated in patients with known hypersensitivity to the drug or its components, as well as those with a history of malignant hyperthermia or myasthenia gravis. It should be used with caution in patients with cardiovascular disease, pulmonary disease, or neuromuscular disorders, as these conditions may increase the risk of adverse effects or complications.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
ADHD | 0.9 | 0.9 | |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.5 | -4 |
Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
Allergies | 0.4 | 0.4 | |
Allergy to milk products | 0 | 0.5 | 0 |
Alopecia (Hair Loss) | 1.1 | 1.1 | |
Alzheimer's disease | 1.1 | 0.4 | 1.75 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | 0 |
Ankylosing spondylitis | 1.6 | 0.3 | 4.33 |
Anorexia Nervosa | 0.5 | 0.1 | 4 |
Antiphospholipid syndrome (APS) | 0.8 | 0.1 | 7 |
Asthma | 0.1 | -0.1 | |
Atherosclerosis | 0.5 | 0.4 | 0.25 |
Atrial fibrillation | 0.9 | 0.6 | 0.5 |
Autism | 1.6 | 1.2 | 0.33 |
Barrett esophagus cancer | 0.3 | 0.4 | -0.33 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.6 | 0.1 | 5 |
Brain Trauma | 0.2 | 0.1 | 1 |
Carcinoma | 1.2 | 0.7 | 0.71 |
Celiac Disease | 0.5 | 0.6 | -0.2 |
Cerebral Palsy | 0.4 | 0.1 | 3 |
Chronic Fatigue Syndrome | 0.6 | 1.4 | -1.33 |
Chronic Kidney Disease | 0.5 | 0.3 | 0.67 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 0.1 | 15 |
Chronic Urticaria (Hives) | 0.5 | 0.5 | |
Coagulation / Micro clot triggering bacteria | 0.9 | 0.6 | 0.5 |
Colorectal Cancer | 2.5 | 0.2 | 11.5 |
Constipation | 0 | 0.1 | 0 |
Coronary artery disease | 0.2 | 0.2 | |
COVID-19 | 1.6 | 1.9 | -0.19 |
Crohn's Disease | 1.9 | 1.1 | 0.73 |
cystic fibrosis | 0 | 0.1 | 0 |
deep vein thrombosis | 0 | 0.6 | 0 |
Depression | 2.6 | 1.6 | 0.63 |
Dermatomyositis | 0.4 | 0.4 | |
Eczema | 0 | 1.3 | 0 |
Endometriosis | 0.9 | 0.9 | |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 1 | 0.5 | 1 |
Fibromyalgia | 0.6 | 0.6 | |
Functional constipation / chronic idiopathic constipation | 0.8 | 0.1 | 7 |
gallstone disease (gsd) | 0.5 | 0.5 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.4 | -0.33 |
Generalized anxiety disorder | 0.4 | 0.4 | |
Glioblastoma | 0.4 | -0.4 | |
Graves' disease | 0.7 | 0.3 | 1.33 |
Halitosis | 0.3 | 0.4 | -0.33 |
Hashimoto's thyroiditis | 0.1 | 0.1 | 0 |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | |
hyperglycemia | 0 | 0.5 | 0 |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 1.1 | 0.7 | 0.57 |
Hypoxia | 0.5 | 0.5 | |
Inflammatory Bowel Disease | 1.5 | 1.7 | -0.13 |
Insomnia | 0.4 | 0.1 | 3 |
Intracranial aneurysms | 0.5 | 0.2 | 1.5 |
Irritable Bowel Syndrome | 0.2 | 0.6 | -2 |
Liver Cirrhosis | 1.5 | 0.7 | 1.14 |
Long COVID | 1.4 | 1.6 | -0.14 |
Low bone mineral density | 0.1 | -0.1 | |
Lung Cancer | 0 | 0 | |
ME/CFS with IBS | 0.4 | 0.4 | |
ME/CFS without IBS | 0.6 | 0.9 | -0.5 |
Metabolic Syndrome | 2.1 | 1.5 | 0.4 |
Mood Disorders | 2.9 | 1.6 | 0.81 |
multiple chemical sensitivity [MCS] | 1.3 | 1.3 | |
Multiple Sclerosis | 2.2 | 2 | 0.1 |
Neuropathy (all types) | 0.4 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.6 | |
Obesity | 1.7 | 1.9 | -0.12 |
obsessive-compulsive disorder | 0.9 | 0.9 | |
Osteoarthritis | 0.4 | 0.4 | |
Osteoporosis | 0 | 0 | |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 1.2 | 1.2 | 0 |
Polycystic ovary syndrome | 0.5 | 0.1 | 4 |
Premenstrual dysphoric disorder | 0.2 | 0.5 | -1.5 |
primary biliary cholangitis | 0.2 | -0.2 | |
Psoriasis | 0.8 | 1.5 | -0.88 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.4 | 0.7 | 2.43 |
Rosacea | 0.1 | -0.1 | |
Schizophrenia | 0.8 | 0.1 | 7 |
scoliosis | 0.1 | -0.1 | |
Sjögren syndrome | 0.9 | 0.5 | 0.8 |
Sleep Apnea | 0.3 | 0.1 | 2 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
Stress / posttraumatic stress disorder | 1 | 0.3 | 2.33 |
Systemic Lupus Erythematosus | 1.3 | 0.1 | 12 |
Tic Disorder | 0.2 | -0.2 | |
Type 1 Diabetes | 0.1 | 0.6 | -5 |
Type 2 Diabetes | 2.1 | 1.4 | 0.5 |
Ulcerative colitis | 0.5 | 0.7 | -0.4 |
Unhealthy Ageing | 1.5 | 0.1 | 14 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.